SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The company disclosed a fundamental shift in business operations from vitamin supplements to oil and gas exploration, representing a material strategic pivot in the registrant's business direction and risk profile.
View raw filing on EDGAR →TransCode posted a corporate presentation to its website on June 18, 2026, disclosing clinical trial progress (Phase 1a and Phase 2a data for TTX-MC138, Phase 3 status for Seviprotimut-L vaccine), pipeline details, and management/advisory board information. While the presentation contains material clinical and operational information relevant to investors, it does not fit neatly into the standard 8-K event categories (no earnings release, executive change, M&A, restatement, impairment, or other discrete triggering event). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) as a non-filed investor presentation, making it a material corporate communication that falls outside the more specific taxonomy.
View raw filing on EDGAR →BrightView extended the maturity of its senior secured term loans from April 2029 to June 2033 (Amendment No. 11 to Credit Agreement) and its receivables financing facility from June 2027 to June 2029 (Sixth Amendment to Receivables Financing Agreement). These refinancings strengthen the company's balance sheet by extending its debt maturity profile and providing additional liquidity runway.
View raw filing on EDGAR →The Company disclosed its net asset value per share of $29.18 as of May 31, 2026 (aggregate NAV of $1.589 billion) and reported that its ongoing private offering has raised $1.748 billion of a $5.0 billion target, providing investors with current valuation and offering progress metrics.
View raw filing on EDGAR →Yorkville filed amended and restated memorandum and articles of association in connection with its IPO, implementing corporate governance amendments required for the company's transition to a publicly traded blank-check SPAC.
View raw filing on EDGAR →FirstCash completed a reincorporation from Delaware to Texas on June 18, 2026, following stockholder approval at the June 9, 2026 Annual Meeting. The Company's governance shifted from Delaware law to Texas law with automatic 1:1 conversion of shares and new Texas Charter/Bylaws, though stockholders' economic rights remain substantially unchanged.
View raw filing on EDGAR →Grace Therapeutics disclosed an update to its corporate presentation on June 18, 2026, which includes material regulatory and clinical information about GTx-104. The presentation details the FDA's Complete Response Letter (CRL) received in April 2026 citing CMC and manufacturing deficiencies (not clinical deficiencies), a scheduled Type A meeting with the FDA, and comprehensive Phase 3 STRIVE-ON trial data showing clinical and pharmacoeconomic benefits over oral nimodipine. While the CRL itself represents a regulatory setback, the disclosure centers on updating investors with the company's regulatory pathway forward and clinical evidence supporting GTx-104's potential. This does not fit neatly into the more specific categories (not a restatement, going concern, impairment, or litigation), but the regulatory status and clinical trial results are material to investor assessment of the company's prospects.
View raw filing on EDGAR →AmperCap Acquisition Company disclosed the consummation of its IPO on June 4, 2026, raising $125 million in gross proceeds from 12.5 million units at $10.00 per unit, plus concurrent private placement proceeds of $5.125 million and subsequent over-allotment exercise proceeds of $18.375 million. While IPO disclosures are typically routine, this filing is material to investors as it establishes the company's capital structure, trust account mechanics ($126.25 million placed in trust), and the framework for a future business combination. The disclosure does not fit neatly into "earnings_release" (no financial results) or other specific event types, making "other_material" the most appropriate classification for this SPAC formation and capitalization event.
View raw filing on EDGAR →Enanta announced advancement of zelicapavir into a registrational Phase 2b/3 clinical trial following a successful End-of-Phase 2 FDA meeting, plus initiation of a pediatric Phase 2b trial, both with topline data expected in 2027. This represents material clinical development progress for a lead program in a clinical-stage biotech company, but does not fit neatly into the standard 8-K event taxonomy (not an earnings release, executive change, M&A, impairment, or other discrete event type). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and is clearly material to investors assessing the company's pipeline advancement and near-term catalysts.
View raw filing on EDGAR →Graham Corporation disclosed slides for its 2026 Investor Day presentation posted to its investor relations website on June 18, 2026, furnished under Item 7.01 (Regulation FD Disclosure). The presentation includes forward-looking guidance on 3-year targets (8-10% incremental margin expansion, >14% organic revenue CAGR, selective M&A, and top-quartile enterprise ROIC through FY27-FY29), strategic initiatives, and detailed business segment performance. While Regulation FD disclosures are typically routine, this presentation contains material forward-looking financial targets and strategic guidance that would affect a reasonable investor's assessment of the company's growth trajectory and capital allocation plans, warranting classification as a material event that does not fit the more specific categories.
View raw filing on EDGAR →Atmos Energy entered into an underwriting agreement on June 15, 2026 to issue $700 million in 4.750% Senior Notes due 2032 in a registered public offering, with expected net proceeds of approximately $693.9 million. While this is a material debt issuance that would affect a reasonable investor's assessment of the company's capital structure and financial position, it does not fit cleanly into the more specific event categories (it is not M&A activity, a restatement, auditor change, going concern, impairment, delisting risk, bankruptcy, covenant breach, cybersecurity incident, dilutive equity issuance, or litigation). The disclosure is a straightforward debt financing announcement properly classified as other material.
View raw filing on EDGAR →Broadcom announced the pricing, expiration, and results of cash tender offers for approximately $2.9 billion in outstanding debt securities, with an upsize of the consideration cap from $2.5 billion to $3.0 billion. While this is a material capital structure transaction affecting the company's debt profile, it does not fit neatly into the standard M&A taxonomy (ma_activity typically covers acquisitions, dispositions, mergers, or changes of control). The tender offer is a debt refinancing/repurchase activity that would materially affect investor assessment of the company's financial position and leverage, but lacks a dedicated 8-K event type.
View raw filing on EDGAR →This disclosure reports the Company's Net Asset Value (NAV) per share as of May 31, 2026, across six classes of common shares and OP Units, calculated in accordance with board-approved valuation guidelines. For a non-traded REIT, NAV per share is a critical metric for investor valuation and redemption pricing, making this material to shareholders. However, it does not fit neatly into the more specific event categories (e.g., earnings_release, which typically involves P&L results rather than NAV-only disclosures), warranting classification as other_material.
View raw filing on EDGAR →This disclosure reports the Company's Net Asset Value (NAV) per share as of May 31, 2026, broken down by share class, along with detailed components of NAV and month-over-month comparison to April 30, 2026. For a non-traded REIT, NAV per share is a critical valuation metric that directly affects investor pricing and redemption decisions. While this is a routine monthly NAV disclosure typical of non-traded REITs, it is material to investors assessing the registrant's value and performance. The event does not fit neatly into more specific categories (not earnings, not an impairment, not a going-concern issue), making "other_material" the most appropriate classification.
View raw filing on EDGAR →NVIDIA completed a $24.5 billion debt offering across seven tranches of senior notes with maturities from 2028 to 2056. While this is a material financing event affecting the company's capital structure and liquidity, it does not fit cleanly into the standard 8-K taxonomy—it is neither a dilutive equity issuance (Item 3.02) nor a covenant breach or going-concern disclosure. The disclosure is routine debt issuance documentation filed under Item 8.01 (Other Events), making "other_material" the most appropriate classification for this significant but structurally standard debt capital raise.
View raw filing on EDGAR →Silvercrest entered into a Second Amendment to its credit agreement with City National Bank, extending the term loan maturity to June 18, 2029 and establishing a $5.0 million term loan commitment plus a $10.0 million revolving facility. This amendment creates a direct financial obligation affecting the company's capital structure and debt obligations.
View raw filing on EDGAR →Whirlpool entered into a First Supplemental Indenture on June 18, 2026, amending the indenture governing its 1.100% Notes due 2027 to accelerate the satisfaction and discharge timeline from one year to two years. This material amendment affects the company's debt obligations and refinancing flexibility.
View raw filing on EDGAR →The board of directors declared a quarterly distribution of $0.25 per share ($1.00 annualized) for American Healthcare REIT shareholders. This distribution declaration is material to investors as it affects shareholder returns and capital allocation expectations, though it does not fit the more specific 8-K event categories.
View raw filing on EDGAR →BCB Bancorp's Board voted to suspend quarterly cash dividends on common and preferred stock and suspend its dividend reinvestment plan, citing the need for capital preservation during a "fulsome evaluation of the Bank's credit portfolios." The CEO explicitly states this decision is to preserve the Bank's "well-capitalized" position, signaling underlying credit or capital concerns. While dividend suspension is material to investors, it does not fit neatly into the more specific event categories (not a restatement, going-concern disclosure, covenant breach, or impairment charge), making "other_material" the most appropriate classification.
View raw filing on EDGAR →This Item 7.01 disclosure announces an updated investor presentation posted to the company's website on June 17, 2026. The presentation contains material forward-looking statements regarding the pending Canyon Creek acquisition, anticipated dividend increases from $1.35 to $1.50 per share post-close, a $1.0Bn Goldman Sachs ABS Warehouse Facility, and a $15Bn acquisition pipeline. While the presentation itself is furnished (not filed) under Regulation FD, the substantive disclosures—particularly the acquisition economics, financing arrangements, and dividend guidance—constitute material updates to investors about the company's strategic direction and financial outlook. This does not fit neatly into the more specific event categories (it is not an earnings release, M&A completion, or compensation arrangement), but the forward-looking guidance and acquisition-related disclosures are material to a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →Cadrenal announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin in Kawasaki disease, which if granted would make the company eligible for a Priority Review Voucher valued at $180–$205 million. The company also disclosed a dual-track portfolio strategy representing a material strategic and regulatory development affecting investor expectations around value creation and capital efficiency.
View raw filing on EDGAR →BiomX disclosed a strategic transition to a defense and security technology holding company and posted an updated investor presentation reflecting this repositioning. While Item 7.01 (Regulation FD Disclosure) is typically used for routine informational updates, the substance here—a completed "fundamental strategic transition" away from legacy clinical-stage biotech activities—is material to investors' understanding of the company's business model, portfolio, and strategy. The press release and presentation emphasize real deployments, customer relationships (Elbit Systems, Rafael), and a new operating framework (Detection-Analysis-Response), which would affect a reasonable investor's assessment. However, this does not fit neatly into the specific event-type taxonomy (not M&A, not an executive change, not a restatement or impairment), so "other_material" is most appropriate.
View raw filing on EDGAR →The disclosure announces the commencement of separate trading of Class A Ordinary Shares and Warrants from Units following the Company's IPO completed on June 4, 2026. This is a routine post-IPO administrative event related to unit separation and listing mechanics. While it affects the trading structure of the Company's securities, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A activity, impairment, covenant breach, or other defined material events). The event is material to investors as it affects how the Company's securities trade, but it is primarily a procedural/administrative disclosure rather than a substantive business or financial event.
View raw filing on EDGAR →The Company filed Amended and Restated Memorandum and Articles of Association effective June 17, 2026, in connection with the completion of its $250 million IPO. While the governing document amendment itself is administrative, the IPO context makes this structural formalization material to investors.
View raw filing on EDGAR →The disclosure announces the completion of a 20-million-unit IPO on May 4, 2026, and the subsequent separation of units into Class A Ordinary Shares and Warrants for trading on NYSE under symbols "QLEP" and "QLEP WS" commencing June 23, 2026. While this is a material capital-raising event, it does not fit neatly into the standard taxonomy: it is neither a traditional earnings release, M&A activity, nor a governance event. The IPO completion and unit separation are significant financial and operational milestones for a blank-check company, warranting classification as a material event outside the defined categories.
View raw filing on EDGAR →The filing discloses the issuance of consolidated obligations (debt securities) totaling approximately $2.463 billion across five tranches with varying maturities and rate structures. While Item 2.03 typically covers creation of direct financial obligations, the Bank's own disclosure states "although consolidated obligation issuance is material to the Bank, we have not made a judgment as to the materiality of any particular consolidated obligation or obligations." The routine, regulatory nature of these debt issuances—combined with the Bank's explicit caveat about materiality—suggests this is a material debt issuance that does not fit cleanly into the standard taxonomy categories, warranting classification as other_material rather than a more specific event type.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (debt securities). The filing reports two debt issuances: a $500 million variable-rate floater note and a $10 million fixed-rate bond. While Item 2.03 is the designated item for debt obligations, the taxonomy lacks a specific "debt_issuance" category. The disclosure is material to investors as it represents new financial obligations and funding activity, but does not fit cleanly into covenant_breach (no breach disclosed) or other more specific event types. This is appropriately classified as other_material given the regulatory framework governing Federal Home Loan Banks and the materiality of consolidated obligations to the institution's operations.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of Consolidated Obligations (debt securities) totaling approximately $13 billion in principal across four bond tranches with trade dates of 6/15/2026. While Item 2.03 is technically designed to capture creation of direct financial obligations, the filing itself explicitly states "although Consolidated Obligations issuance is material to the FHLB, we have not made a judgment as to the materiality of any particular Consolidated Obligation or Obligations." The disclosure is routine debt issuance reporting for a Federal Home Loan Bank, not a covenant breach, going-concern issue, or other acute financial stress signal. The event is material to investors as a major funding activity, but does not fit cleanly into the more specific event categories (covenant_breach, going_concern, material_impairment, etc.), warranting classification as other_material.
View raw filing on EDGAR →This Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $10 billion in principal across multiple tranches with varying maturities and rate structures. While Item 2.03 is the designated item for debt obligations, the taxonomy lacks a specific "debt_issuance" category. The disclosure is material to investors as it represents significant new debt financing, but does not fit cleanly into covenant_breach (no breach alleged), ma_activity (not a merger/acquisition), or other more specific event types. The filing explicitly notes that "consolidated obligations issuance is material to the FHLBank," supporting materiality.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $2.8 billion across multiple tranches with varying maturities and rate structures. While Item 2.03 is technically designed for creation of direct financial obligations, the filing itself explicitly states "although consolidated obligations issuance is material to the Bank, we have not made a judgment as to the materiality of any particular consolidated obligation or obligations." The disclosure is routine for a Federal Home Loan Bank's ordinary course debt issuance operations, but the aggregate principal amount and the fact that it triggers Item 2.03 filing indicate materiality to investors tracking the Bank's capital structure and funding activities.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $415 million across six tranches on trade dates of 6/15–6/16/2026. While Item 2.03 typically signals covenant breaches or direct financial obligations under off-balance-sheet arrangements, this filing discloses routine debt issuances by a Federal Home Loan Bank in the ordinary course of business. The disclosure is material to investors (debt issuances affect the registrant's capital structure and leverage), but does not fit the specific "covenant_breach" taxonomy, which contemplates triggering events that accelerate obligations or indicate financial stress. This is a standard debt capital-raising activity disclosed under the appropriate Item, best classified as "other_material" rather than forcing it into a misaligned category.
View raw filing on EDGAR →The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds totaling approximately $147.5 million with a settlement date of 6/22/2026 and maturity of 6/22/2028. While Item 2.03 is titled "Creation of a Direct Financial Obligation," this disclosure is a routine issuance of consolidated obligations by a Federal Home Loan Bank—a government-sponsored enterprise with a statutory mandate to issue such debt. The event is material in amount but lacks the characteristics of a covenant breach, debt acceleration, or financial distress signal that would typically trigger heightened investor concern at a commercial entity. The disclosure is administrative in nature for this type of regulated institution.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling approximately $838.5 million across seven bond tranches with varying maturities (6 months to 4 years) and rate structures. While Item 2.03 is nominally designed to capture debt covenant breaches and off-balance-sheet arrangements, the filing itself explicitly states the Bank "has not made a judgment as to the materiality of these consolidated obligation bonds" and the disclosure is routine debt issuance reporting for a Federal Home Loan Bank. The event does not fit cleanly into the more specific taxonomy categories (covenant_breach applies to triggering events that accelerate obligations, not routine issuances), making other_material the most appropriate classification for this material but administratively routine debt disclosure.
View raw filing on EDGAR →The disclosure announces preclinical data demonstrating that KIO-300 significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model, with statistically significant results (p < 0.0001). While this represents early-stage research outside the company's primary ophthalmology focus, the data suggests potential therapeutic expansion into neurology and epilepsy treatment. This is material to investors as it expands the perceived value of the ion channel modulator platform beyond retinal disease, though it does not fit neatly into the standard event taxonomy (not an earnings release, M&A activity, executive change, or other specifically defined categories).
View raw filing on EDGAR →CervoMed received a notice of allowance from the USPTO for a patent protecting neflamapimod for treating dementia with Lewy bodies, extending intellectual property protection to 2042. While patent issuances are generally positive developments for biopharmaceutical companies, this disclosure does not fit cleanly into the standard 8-K event taxonomy (not an earnings release, executive change, M&A activity, impairment, or litigation). The patent protection is material to investors assessing the company's competitive position and product pipeline, warranting classification as other_material.
View raw filing on EDGAR →Omeros entered into privately negotiated agreements to repurchase approximately $16.0 million principal amount of its 9.50% Convertible Senior Notes due 2029 for up to $34.0 million total consideration. This is a material debt management transaction affecting the company's capital structure and leverage, but does not fit cleanly into the standard taxonomy categories (not a covenant breach, restatement, impairment, or other specifically enumerated event type). The repurchase reduces outstanding debt and represents a significant use of capital.
View raw filing on EDGAR →This is a shareholder letter disclosing strategic business updates, regulatory milestones, and capital allocation plans following a recent capital raise. While it contains forward-looking statements about regulatory submissions (CardiAMP PMDA submission in Q4 2026), clinical trial enrollment, and partnership opportunities, it does not constitute a discrete material event from the taxonomy (not an earnings release, M&A activity, executive change, impairment, covenant breach, or other specific event type). The disclosure is material to investors as it outlines near-term catalysts and business strategy, but the Item 7.01 Regulation FD format and content—a strategic update rather than a specific triggering event—best fits "other_material."
View raw filing on EDGAR →ReposiTrak declared a quarterly cash dividend of $0.02 per share ($0.08 annually), payable August 14, 2026 to shareholders of record on June 30, 2026. While dividend declarations are material corporate actions affecting shareholder value, they do not fit cleanly into the more specific event categories (earnings_release, exec_departure, M&A, etc.). This is classified as other_material because it represents a significant capital allocation decision that would affect a reasonable investor's assessment of the company's financial policy and cash position.
View raw filing on EDGAR →Enphase entered into a Tax Credit Transfer Agreement to sell up to $150 million in advanced manufacturing production tax credits (Section 45X) for up to $139.5 million in cash payments over 2026-2027. While this is a material transaction affecting liquidity and cash flow, it does not fit cleanly into the standard M&A, financing, or compensation categories—it is a specialized tax credit monetization arrangement. The materiality is evident from the substantial dollar amounts and the Company's explicit forward-looking statements about its ability to generate and receive payments for such credits.
View raw filing on EDGAR →Dragonfly Energy announced receipt of a patent allowance from the USPTO for "Powderized Solid-State Electrolyte and Electroactive Materials," directed at manufacturing processes supporting the company's solid-state battery development. While this is a positive intellectual property development, it does not fit neatly into the standard 8-K event taxonomy (not earnings, M&A, executive changes, impairments, etc.). Patent allowances can be material to technology companies' competitive positioning and future revenue potential, particularly in battery development where IP is strategically important.
View raw filing on EDGAR →The filing discloses an extension of the maturity date of a $3,000,000 unsecured revolving note from July 5, 2026 to July 7, 2027. While this is a material financing arrangement with a related party (ProdActive II, LLC, linked to the Founder/CEO), it does not fit cleanly into the standard taxonomy: it is neither a new debt covenant breach, a dilutive issuance, nor a traditional M&A event. The extension preserves access to low-interest financing and is material to investor assessment of the company's liquidity and capital structure, but the specific event—a maturity extension rather than a new borrowing or default—is best classified as other_material.
View raw filing on EDGAR →The filing discloses a comprehensive update on Eightco's treasury composition and strategic holdings as of June 18, 2026, totaling approximately $472 million. The press release highlights material positions in OpenAI ($90M), Beast Industries ($18M), 283+ million WLD tokens, and 16,278 ETH, along with significant cash holdings. While this is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a traditional earnings release, the detailed quantification of material assets and strategic investments would affect a reasonable investor's assessment of the company's financial position and asset base. The disclosure does not fit neatly into earnings_release (no financial results), ma_activity (no transaction), or other specific categories, making other_material the most appropriate classification.
View raw filing on EDGAR →The filing discloses termination of a technology license agreement and services agreement with Lightning Silicon Technology, Inc., coupled with a complete exit from equity holdings in both LST and LS Assets through share repurchases for nominal consideration ($1.00 each for 18 million shares). While the company states it does not expect material financial effects, the termination of a technology license and complete divestiture of equity stakes in what appears to be a significant business relationship represents a material strategic event affecting the registrant's business operations and future revenue streams (including the royalty arrangement through October 2026).
View raw filing on EDGAR →PHP Ventures Acquisition Corp. disclosed under Item 8.01 that it deposited $957.30 into its trust account to extend the deadline for completing an initial business combination by one month (from June 16 to July 16, 2026). This is a material event for a SPAC facing a deadline extension, though it does not fit neatly into the standard taxonomy categories. The company was already suspended from Nasdaq trading as of April 2024, making the extension effort material to investors assessing the registrant's viability.
View raw filing on EDGAR →The filing discloses a $50,000 extension payment deposited into the trust account to extend the business combination deadline by one month (from June 19 to July 19, 2026), reported under Item 2.03 (Creation of a Direct Financial Obligation). While this creates a direct financial obligation, it does not fit neatly into the standard taxonomy categories—it is neither a covenant breach (no violation), nor a dilutive issuance, nor M&A activity per se, but rather a procedural extension mechanism for a SPAC. The materiality is moderate: it signals the company has not yet completed its business combination and is incurring costs to extend the deadline, which is relevant to investors assessing the SPAC's progress and timeline.
View raw filing on EDGAR →Bandwidth Inc. repurchased approximately $122.5 million in aggregate principal amount of its 2028 notes for $116.5 million in cash, reducing outstanding debt by over 80% and materially altering the company's financial structure and leverage profile.
View raw filing on EDGAR →Liberty Media announced the closing of a debt repricing for its MotoGP subsidiary, reducing total debt by approximately $114 million equivalent and lowering interest margins on Term Loan B (from 2.50% to 2.25%) and adjusting leverage-based pricing bands. While this is a material refinancing event affecting a significant subsidiary's capital structure and debt service costs, it does not fit cleanly into the standard 8-K taxonomy—it is neither a covenant breach, a material impairment, nor a traditional M&A activity, but rather a proactive debt restructuring disclosed under Regulation FD.
View raw filing on EDGAR →Advanced Drainage Systems disclosed a 2026 Investor Day event with presentation of fiscal 2030 outlook and growth projections. While Item 7.01 (Regulation FD Disclosure) is typically used for non-material investor communications, the disclosure of forward-looking guidance for fiscal 2030 targets (10% CAGR sales growth, 28-29% margin expansion, 45-50% free cash flow conversion) and unveiling of a multi-year strategic outlook constitutes material forward-looking information that would affect investor assessment. However, this does not fit neatly into the specific event taxonomy (not earnings release, not M&A, not an executive change, etc.), warranting classification as other_material.
View raw filing on EDGAR →Alight announced a 1-for-20 reverse stock split effective June 30, 2026, approved by stockholders at the June 10, 2026 Annual Meeting. While reverse stock splits are structural actions that do not change economic ownership, this disclosure is material because it affects the total mix of information available to investors—particularly regarding the company's compliance with NYSE listing standards (the press release explicitly states the split "affirms the Company's commitment to remain on the NYSE by meeting the NYSE's price criteria for continued listing"). The event does not fit neatly into the specific taxonomy categories (not a delisting risk per se, but rather a proactive measure to avoid one), making "other_material" the most appropriate classification.
View raw filing on EDGAR →Voyager Technologies completed a redomestication from Delaware to Texas on June 18, 2026, converting from a Delaware corporation to a Texas corporation. This structural change materially modifies the governance framework and stockholder rights by shifting from Delaware General Corporation Law to Texas Business Organizations Code, affecting the legal rights and protections of shareholders.
View raw filing on EDGAR →